Developer docs
API playgroundTry for free, no card

Search company profiles

Until Labs

Full company profile

uuid00003ti

Namestring
Until Labs
Legal namestring
Until Labs
Websiteurl
untillabs.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Until Labs is a San Francisco-based biotechnology company developing reversible cryopreservation technology to extend the viability of donor organs for transplantation. The near-term application targets the US organ transplant market, where roughly 100,000+ patients are on waiting lists, approximately 46,000 receive organs annually, and about 11,858 organs fail to reach patients each year largely because of short viability windows (4-8 hours for hearts and lungs, 24-36 hours for kidneys). The long-term vision extends to whole-body medical hibernation for terminal patients awaiting breakthrough treatments, with organ-scale work positioned as a de-risking path toward that broader goal.

The core platform integrates four technology pillars: (1) novel cryoprotectant formulations designed using molecular dynamics simulations and machine learning to prevent ice formation while minimizing toxicity, (2) perfusion protocols that use the organ's own vascular network to deliver cryoprotectants and iron-oxide nanoparticles uniformly, (3) cooling hardware that achieves vitrification below -130°C where water turns to glass, and (4) volumetric rewarming using alternating magnetic field (AMF) coils. The Until Mark I Rewarming System produces a 900 kHz oscillating field at up to 40 kA/m while consuming under 4 kW of power, compatible with standard hospital electrical infrastructure. Key scientific milestones include the recovery of electrical activity from cryopreserved and rewarmed rodent neural tissue (June 2024) and the successful volumetric rewarming of a vitrified pig kidney (May 2026).

The company is pre-revenue and in the R&D phase. Its planned go-to-market is enterprise field sales targeting transplant centers and organ procurement organizations, with planned revenue streams from organ cryopreservation services (recurring) and longer-term technology licensing. Pricing is not publicly disclosed. As of September 2025, Until Labs had raised $100M+ in total funding, including a $58M Series A led by Founders Fund with Lux Capital and Field Ventures participating, and operates with an interdisciplinary team of approximately 40+ scientists, engineers, surgeons, and operations staff led by co-founders Laura Deming (CEO) and Hunter Davis Ozawa (CSO).

Short descriptiontext

Until Labs is a San Francisco-based biotechnology company developing reversible cryopreservation technology to extend donor organ viability for transplantation, with a long-term vision of enabling whole-body medical hibernation for terminal patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
organ cryopreservation, vitrification technology, transplant preservation, biomedical engineering, cryoprotectant chemistry
Industry3 codes
PRIMARYHLAAAJAN
Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGAGAK
Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAIAJ
Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Organ Cryopreservation Technology
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Organ Cryopreservation Services
TypeSubscription Recurring
Description

The company plans to generate revenue through organ cryopreservation products and services for transplant centers, enabling indefinite storage and rewarming of donor organs

untillabs.com
2Technology Licensing
TypeLicensing Royalties
Description

Long-term potential for licensing cryopreservation technology, protocols, and equipment to healthcare institutions

biospace.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Until Labs is developing a reversible cryopreservation platform for human donor organs that combines novel cryoprotectant formulations, perfusion and surgical protocols, and custom cooling and rewarming hardware to vitrify organs at subzero temperatures without ice formation and revive them uniformly for transplant. The company's first commercial sub-product is the Until Mark I rewarming system, an alternating magnetic field device paired with iron-oxide nanoparticles that achieves hospital-compatible volumetric rewarming of vitrified organs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Kidney viability window extended from 24-36 hours to potentially weeks or months
+2 more records
Product overview1 text field

Until Labs offers a unified reversible cryopreservation platform centered on enabling indefinite storage and rewarming of donor organs for transplant. The core platform integrates novel cryoprotectant formulations, perfusion and surgical protocols, and cooling/rewarming hardware to safely vitrify and revive human organs. A key sub-product is the Until Mark I Rewarming System, an AMF-based volumetric rewarming device that uses iron-oxide nanoparticles and alternating magnetic fields to achieve rapid, uniform organ rewarming at hospital-compatible power levels. The company also applies its technology toward longer-term whole-body medical hibernation.

Product and service2 records
1Until Reversible Cryopreservation Platform
CategoryOrgan Cryopreservation Technology
Description

An integrated technology platform for reversible cryopreservation of human donor organs that combines novel cryoprotectant formulations, perfusion and surgical protocols, and cooling and rewarming hardware to safely vitrify organs at subzero temperatures without ice formation and rewarm them uniformly for transplant. Intended for use by transplant centers and organ procurement organizations to extend organ viability from hours to weeks or months.

2Until Mark I Rewarming System
CategoryMedical Hardware / Organ Rewarming Equipment
Description

A volumetric organ rewarming system built around an alternating magnetic field (AMF) coil that produces a 900 kHz oscillating field at up to 40 kA/m and 7 kW of coil loss. Iron-oxide nanoparticles are perfused through the organ's vasculature to generate uniform, rapid heat when exposed to the AMF field. Designed to be hospital-compatible and has demonstrated rewarming of a vitrified pig kidney at 50–73°C/min while consuming under 4 kW of power from standard electrical infrastructure.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1TransMedics Group
TypeDirect peer
Description

TransMedics commercializes the Organ Care System (OCS) for lung, heart, and liver — a normothermic perfusion platform that keeps donor organs alive during transport. It is the most advanced commercial competitor in extending organ viability and viability windows, directly addressing the same transplant-center pain point Until Labs targets.

TypeDirect peer
Description

OrganOx developed the metra normothermic liver perfusion device, FDA-cleared and commercially used in transplant centers worldwide. Like Until Labs, it focuses on extending organ preservation and viability windows for transplant, making it a direct competitive peer in target market and use case.

TypeDirect peer
Description

XVivo Perfusion provides machine perfusion and preservation solutions for lungs, hearts, livers, and kidneys (e.g., XPS, LS™, Kidney Perfusion). It targets the same transplant-center customers and overlaps directly with Until Labs' value proposition of extending organ viability.

TypeDirect peer
Description

Paragonix commercializes FDA-cleared hypothermic preservation and transport devices for donor hearts, lungs, and kidneys (SherpaPak, LUNGguard, KidneyVault). It competes for the same transplant-center procurement budgets and addresses organ viability — a direct peer on technology approach and customer.

TypeDirect peer
Description

Bridge to Life supplies clinical-grade organ preservation solutions (e.g., Belzer UW, IGL-1) and is a major incumbent in cold-storage solutions used by transplant centers. It is comparable to Until Labs in serving organ preservation workflows, though its technology (chemical cold storage) is adjacent rather than overlapping.

6Arigos Biomedical
TypeEmerging player
Description

Arigos Biomedical is developing high-subzero vitrification and cryogenic storage technology for organs, including acquired technology from 21st Century Medicine. It is one of the closest direct technology competitors to Until Labs' vitrification platform, though it remains at an earlier commercialization stage.

TypeEmerging player
Description

Ossium Health cryopreserves bone marrow and is developing cryopreserved cellular therapeutics from deceased donor tissue, using related cryobiology and GMP cryopreservation infrastructure. It is comparable as a peer applying cryopreservation to transplant-relevant biological materials.

TypeBroad incumbent
Description

United Therapeutics is a public biotech that has invested heavily in xenotransplantation and anti-rejection technologies, including the acquisition of Sylvatica Biotech for organ cryopreservation capabilities. It is comparable as a broader incumbent pursuing organ supply solutions, with cryopreservation as one strategic pillar.

TypeOthers
Description

21st Century Medicine pioneered whole-organ vitrification technology (notably rabbit kidney work published in Nature Communications), with technology later acquired by Arigos Biomedical. It is comparable as a historical scientific predecessor in the vitrification space underlying Until Labs' approach.

10Global Transplant Solutions
TypeRegional player
Description

Global Transplant Solutions distributes preservation and transplant-related supplies and devices to organ procurement organizations and transplant centers. It is comparable as a participant in the same transplant-center procurement ecosystem Until Labs targets, though it operates primarily as a distributor rather than a technology developer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Until Labs

Organ Cryopreservation Technologyuntillabs.com

Until Labs is a San Francisco-based biotechnology company developing reversible cryopreservation technology to extend donor organ viability for transplantation, with a long-term vision of enabling whole-body medical hibernation for terminal patients.

What Until Labs does

Until Labs is a San Francisco-based biotechnology company developing reversible cryopreservation technology to extend the viability of donor organs for transplantation. The near-term application targets the US organ transplant market, where roughly 100,000+ patients are on waiting lists, approximately 46,000 receive organs annually, and about 11,858 organs fail to reach patients each year largely because of short viability windows (4-8 hours for hearts and lungs, 24-36 hours for kidneys). The long-term vision extends to whole-body medical hibernation for terminal patients awaiting breakthrough treatments, with organ-scale work positioned as a de-risking path toward that broader goal.

The core platform integrates four technology pillars: (1) novel cryoprotectant formulations designed using molecular dynamics simulations and machine learning to prevent ice formation while minimizing toxicity, (2) perfusion protocols that use the organ's own vascular network to deliver cryoprotectants and iron-oxide nanoparticles uniformly, (3) cooling hardware that achieves vitrification below -130°C where water turns to glass, and (4) volumetric rewarming using alternating magnetic field (AMF) coils. The Until Mark I Rewarming System produces a 900 kHz oscillating field at up to 40 kA/m while consuming under 4 kW of power, compatible with standard hospital electrical infrastructure. Key scientific milestones include the recovery of electrical activity from cryopreserved and rewarmed rodent neural tissue (June 2024) and the successful volumetric rewarming of a vitrified pig kidney (May 2026).

The company is pre-revenue and in the R&D phase. Its planned go-to-market is enterprise field sales targeting transplant centers and organ procurement organizations, with planned revenue streams from organ cryopreservation services (recurring) and longer-term technology licensing. Pricing is not publicly disclosed. As of September 2025, Until Labs had raised $100M+ in total funding, including a $58M Series A led by Founders Fund with Lux Capital and Field Ventures participating, and operates with an interdisciplinary team of approximately 40+ scientists, engineers, surgeons, and operations staff led by co-founders Laura Deming (CEO) and Hunter Davis Ozawa (CSO).

Until Labs firmographics

Firmographics
Name
Until Labs
Legal name
Until Labs
Website
https://untillabs.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Until Labs is a San Francisco-based biotechnology company developing reversible cryopreservation technology to extend donor organ viability for transplantation, with a long-term vision of enabling whole-body medical hibernation for terminal patients.
Ownership category
akta.pro rank

Until Labs industry classification

Industry
Product category
Organ Cryopreservation Technology
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAJAN
Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGAGAK
Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAIAJ
Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats)

Keywords

  • Organ cryopreservation
  • Vitrification technology
  • Transplant preservation
  • Biomedical engineering
  • Cryoprotectant chemistry

Where Until Labs is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Until Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Organ Cryopreservation Services: The company plans to generate revenue through organ cryopreservation products and services for transplant centers, enabling indefinite storage and rewarming of donor organs
  2. Technology Licensing: Long-term potential for licensing cryopreservation technology, protocols, and equipment to healthcare institutions

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Until Labs product offering

Product offering

Core offering

Until Labs is developing a reversible cryopreservation platform for human donor organs that combines novel cryoprotectant formulations, perfusion and surgical protocols, and custom cooling and rewarming hardware to vitrify organs at subzero temperatures without ice formation and revive them uniformly for transplant. The company's first commercial sub-product is the Until Mark I rewarming system, an alternating magnetic field device paired with iron-oxide nanoparticles that achieves hospital-compatible volumetric rewarming of vitrified organs.

Product overview

Until Labs offers a unified reversible cryopreservation platform centered on enabling indefinite storage and rewarming of donor organs for transplant. The core platform integrates novel cryoprotectant formulations, perfusion and surgical protocols, and cooling/rewarming hardware to safely vitrify and revive human organs. A key sub-product is the Until Mark I Rewarming System, an AMF-based volumetric rewarming device that uses iron-oxide nanoparticles and alternating magnetic fields to achieve rapid, uniform organ rewarming at hospital-compatible power levels. The company also applies its technology toward longer-term whole-body medical hibernation.

Differentiator

Problem solved

Functional benefit

Products and services

  • Until Reversible Cryopreservation Platform An integrated technology platform for reversible cryopreservation of human donor organs that combines novel cryoprotectant formulations, perfusion and surgical protocols, and cooling and rewarming hardware to safely vitrify organs at subzero temperatures without ice formation and rewarm them uniformly for transplant. Intended for use by transplant centers and organ procurement organizations to extend organ viability from hours to weeks or months.
  • Until Mark I Rewarming System A volumetric organ rewarming system built around an alternating magnetic field (AMF) coil that produces a 900 kHz oscillating field at up to 40 kA/m and 7 kW of coil loss. Iron-oxide nanoparticles are perfused through the organ's vasculature to generate uniform, rapid heat when exposed to the AMF field. Designed to be hospital-compatible and has demonstrated rewarming of a vitrified pig kidney at 50–73°C/min while consuming under 4 kW of power from standard electrical infrastructure.

Quantifiable outcome

  • Kidney viability window extended from 24-36 hours to potentially weeks or months
  • +2 more outcomes

Companies that use Until Labs

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Until Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Until Labs partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Until Labs competitors and assessment

Company assessment

Direct peers

  • TransMedics Group: TransMedics commercializes the Organ Care System (OCS) for lung, heart, and liver — a normothermic perfusion platform that keeps donor organs alive during transport. It is the most advanced commercial competitor in extending organ viability and viability windows, directly addressing the same transplant-center pain point Until Labs targets.
  • OrganOx: OrganOx developed the metra normothermic liver perfusion device, FDA-cleared and commercially used in transplant centers worldwide. Like Until Labs, it focuses on extending organ preservation and viability windows for transplant, making it a direct competitive peer in target market and use case.
  • XVivo Perfusion: XVivo Perfusion provides machine perfusion and preservation solutions for lungs, hearts, livers, and kidneys (e.g., XPS, LS™, Kidney Perfusion). It targets the same transplant-center customers and overlaps directly with Until Labs' value proposition of extending organ viability.
  • Paragonix Technologies: Paragonix commercializes FDA-cleared hypothermic preservation and transport devices for donor hearts, lungs, and kidneys (SherpaPak, LUNGguard, KidneyVault). It competes for the same transplant-center procurement budgets and addresses organ viability — a direct peer on technology approach and customer.
  • Bridge to Life: Bridge to Life supplies clinical-grade organ preservation solutions (e.g., Belzer UW, IGL-1) and is a major incumbent in cold-storage solutions used by transplant centers. It is comparable to Until Labs in serving organ preservation workflows, though its technology (chemical cold storage) is adjacent rather than overlapping.

Emerging players

  • Arigos Biomedical: Arigos Biomedical is developing high-subzero vitrification and cryogenic storage technology for organs, including acquired technology from 21st Century Medicine. It is one of the closest direct technology competitors to Until Labs' vitrification platform, though it remains at an earlier commercialization stage.
  • Ossium Health: Ossium Health cryopreserves bone marrow and is developing cryopreserved cellular therapeutics from deceased donor tissue, using related cryobiology and GMP cryopreservation infrastructure. It is comparable as a peer applying cryopreservation to transplant-relevant biological materials.

Broad incumbents

  • United Therapeutics: United Therapeutics is a public biotech that has invested heavily in xenotransplantation and anti-rejection technologies, including the acquisition of Sylvatica Biotech for organ cryopreservation capabilities. It is comparable as a broader incumbent pursuing organ supply solutions, with cryopreservation as one strategic pillar.

Others

  • 21st Century Medicine: 21st Century Medicine pioneered whole-organ vitrification technology (notably rabbit kidney work published in Nature Communications), with technology later acquired by Arigos Biomedical. It is comparable as a historical scientific predecessor in the vitrification space underlying Until Labs' approach.

Regional players

  • Global Transplant Solutions: Global Transplant Solutions distributes preservation and transplant-related supplies and devices to organ procurement organizations and transplant centers. It is comparable as a participant in the same transplant-center procurement ecosystem Until Labs targets, though it operates primarily as a distributor rather than a technology developer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Until Labs social profiles

Digital presence

Until Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Until Labs leadership team

Management profile

Number of profiles

Profiles8 records

Until Labs funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Until Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Until Labs

What does Until Labs do?

Until Labs is developing a reversible cryopreservation platform for human donor organs that combines novel cryoprotectant formulations, perfusion and surgical protocols, and custom cooling and rewarming hardware to vitrify organs at subzero temperatures without ice formation and revive them uniformly for transplant. The company's first commercial sub-product is the Until Mark I rewarming system, an alternating magnetic field device paired with iron-oxide nanoparticles that achieves hospital-compatible volumetric rewarming of vitrified organs.

Is Until Labs a public or private company?

Until Labs is a private company. It is classified as venture growth investor backed and is currently operating.

When was Until Labs founded?

Until Labs was founded in 2016. It employs 11 to 50 people.

Where is Until Labs based?

Until Labs is headquartered in San Francisco, United States, in the North America region.

How does Until Labs make money?

Two revenue lines are on record. Organ Cryopreservation Services are the primary driver. The others are technology Licensing.

Who are Until Labs's main competitors?

Direct peers on record are TransMedics Group, OrganOx, XVivo Perfusion, Paragonix Technologies and Bridge to Life. Emerging players are Arigos Biomedical and Ossium Health. United Therapeutics is listed as a broad incumbent. 21st Century Medicine is listed as an others. Global Transplant Solutions is listed as a regional player.

Does Until Labs have an API?

No public API is recorded for Until Labs.

What industry is Until Labs in?

Until Labs's product category is Organ Cryopreservation Technology. Its primary akta.pro industry code is HLAAAJAN, Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies, with a secondary code of HLAGAGAK, Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ObserverThe Executive Who Sells Cryonics to the Ultra-Wealthy Chasing ImmortalityJames Arrowood, CEO of Alcor Life Extension Foundation, oversees a Scottsdale-based nonprofit that cryopreserves human bodies and heads for about 1,600 members at costs of $220,000 for whole-body preservation or $80,000 for neuropreservation, with ultra-wealthy clients representing roughly 20 percent of membership. The article details how tech billionaires including Peter Thiel, Jeff Bezos, and Sam Altman have collectively invested an estimated $5 billion into longevity and cryonics ventures over the past 25 years, creating new competition for Alcor from companies like Until Labs, which raised $58 million in a Founders Fund-led round. Scientific experts interviewed expressed skepticism, with McGill University's Michael Hendricks stating that only a handful of neuroscientists take the concept seriously, while Arrowood himself acknowledges revival remains an aspirational goal.BioSpaceUntil Labs Announces $58M Series A Funding Round, to Develop an Organ Cryopreservation Product for Transplant Patients and SurgeonsUntil Labs announced a $58 million Series A funding round led by Founders Fund, with participation from Lux Capital and Field Ventures, bringing total investment to over $100 million. The company develops perfusion hardware, cryoprotective agents, and rewarming infrastructure for reversible organ cryopreservation to enable indefinite storage and improved organ matching for transplant patients. The funding will be used to expand the multidisciplinary team across chemistry, biology, engineering, neuroscience, and surgery as the company works toward its goal of whole-body medical hibernation technology.GlobeNewswireUntil Labs Announces $58M Series A Funding Round, to Develop an Organ Cryopreservation Product for Transplant Patients and SurgeonsUntil Labs announced a $58 million Series A funding round led by Founders Fund, with participation from Lux Capital and Field Ventures. The company develops perfusion hardware, cryoprotective agents, and rewarming infrastructure for reversible cryopreservation of biological systems, focusing on organs for transplants.Venture Capital Access OnlineUntil Labs Announces $58M Series A Funding Round, to Develop an Organ Cryopreservation Product for Transplant Patients and SurgeonsUntil Labs announced a $58 million Series A funding round led by Founders Fund, with participation from Lux Capital and Field Ventures, bringing the company's total investment to date to over $100 million. The funding will be used to build out the company's multidisciplinary team across chemistry, biology, engineering, and surgery, as well as operational infrastructure for developing organ cryopreservation technology. The company's technology aims to preserve donor organs at indefinite storage temperatures and rewarm them for transplant, addressing the challenge of organ matching and reducing organ waste due to time constraints.UntillabsuntilUntil closed a $58 million Series A funding round led by Founders Fund, with Lux and Field Ventures participating, to advance its organ cryopreservation technology. The company is developing reversible cryopreservation methods using novel molecular agents, perfusion protocols, and cooling/rewarming hardware to extend organ viability beyond current time constraints of 4-36 hours depending on organ type. Until cited that approximately 46,000 of the ~106,000 patients on transplant waitlists in 2024 received organs, with thousands more lost annually due to logistical delays.HIT ConsultantUntil Labs Raises $58M to Pioneer Organ Cryopreservation and Medical HibernationUntil Labs, a biotechnology company developing reversible cryopreservation technology for biological systems, has raised $58 million in Series A funding led by Founders Fund with participation from Lux Capital and Field Ventures. The funding will be used to expand the company's multidisciplinary team and advance organ-scale cryopreservation, which aims to preserve donor organs indefinitely for transplant rather than the current 4-36 hour window. The company's long-term vision is to develop whole-body medical hibernation technology.